戻る Agenda
Session 10: New Drugs of 2015 Review and Closing Remarks
Session Chair(s)
Craig Klinger, RPH
Retired Director - Global MSL Trainer, The Office of Medical Professional Develo
Eli Lilly and Company, United States
Update your knowledge on drugs that have been approved or have been given new indications or line extensions by the FDA in 2015. A unique New Drug Comparison Rating (NDCR) system will be reviewed to allow the participant to understand the features of new drugs and explain their role among currently available therapies.
Learning Objective : - Identify the indications & routes of administration of the new therapeutic agents
- Describe the important pharmacokinetic properties & the unique characteristics of the new drugs
- Restate the most important adverse events & precautions of the new drugs
- Compare the new drugs to the older therapeutic agents to which they are most similar in activity
- Assess information regarding the new drugs that should be communicated to patients
Speaker(s)
Speaker
Daniel A Hussar, PHD, MS
Philadelphia College of Pharmacy, University of the Sciences In Philadelphia, United States
Remington Professor of Pharmacy